Xantho Bio. attended Bio Japan 2024 for global business partnering
The CEO and BD manager of Xantho Bio. attended Bio Japan 2024, one of the largest Bio convention in Asia, held in PACIFICO Yokohama Convention Center, Japan (from October 9 to October 11). During the 3-day event, Xantho Bio. participated in the one-on-one partnering meetings with international pharmaceutical companies to discuss drug licensing opportunities.
Xantho Bio. presented in the 39th Natural Products Symposium
Xantho Bio. participated in the 39th Natural Products Symposium and the 24th Society for Free Radical Research-Taiwan Symposium, co-hosted by National Taiwan University and Chang Gung University of Science and Technology, held from October 4th to 6th this year for three days of academic activities.
Attended BIO 2024 for global business partnering
Xantho Bio.participated in the BIO2024 in San Diego US, from June 3 to June 6, 2024, as part of the Taiwan delegation.
GM-XANTHO Phase 2a Clinical Progress
GM-XANTHO Phase 2a Clinical Progress Has Reached 80%.
Congrats! Taiwan invention patents have been granted for GM-XAN005 and GM-XAN006 in September 2023
Taiwan invention patents have been granted respectively for drug GM-XAN005 in the diabetic wound indication and for drug GM-XAN006 in the burn wound indication in September 2023.
Congrats! India Patent has been granted
Patent of GM-XANTHO has been granted by Directorate General of Intellectual Property(DGIP) in India in Apr 2023.
Clinical Phase I in Taiwan
On Nov, 2019, Xantho Bio. successfully obtained a permit of IND from Taiwan TFDA. Completed Phase I on Jan 2021. Conduct clinical Phase IIa on Apr 2021 in NTUH.